Follow the research.
Start with a compound. Explore the studies. Keep the question, the population, and the limitations together.
A curated starting point, not an exhaustive or systematic review. Each paper has an original plain-English summary and a link to its source.
What the labels
actually mean.
More papers does not automatically mean stronger evidence. Study quality, consistency, directness, and the question being asked matter.
Read the evidence guide →Human, animal, cell, review, or registry?
Human includes controlled trials, observational studies, and case reports. These are not interchangeable: the design is shown on each entry. Animal studies and cell or laboratory experiments can explore mechanisms but cannot establish clinical benefit. Reviews summarize other work. Registered trials describe planned or ongoing studies; registration alone is not a result.
For mixed experiments, the badge reflects the intervention evidence summarized. A human observation of a naturally occurring peptide does not turn an animal treatment experiment into a human treatment trial.
Some human studies measure hormone levels or other markers rather than symptoms or health outcomes. Some analytical papers identify a substance rather than test a treatment. Read the study question before the result.
How papers are selected and checked
This initial selection prioritizes identifiable primary research directly relevant to each named compound, with controlled human studies where available, and important neutral findings or safety limits. It does not include every paper or use a systematic-review search protocol.
Citations, intervention identity, publication details, and linked records were checked against journal articles, PubMed, or other primary records. A sample size is shown when it can be established from the source reviewed. Missing details are left explicit rather than guessed.
The review date records this curation pass, not the age of the research. Updates happen when requested; there is no automatic refresh.
Similar names can mean different interventions
TB-500 is not interchangeable with every thymosin β4 preparation. IGF-1 LR3 is not ordinary IGF-1. Epitalon is not Epithalamin. Kisspeptin-10 is not kisspeptin-54. CJC-1295 trials may concern a long-acting, albumin-binding formulation. Identity notes and evidence gaps flag these differences.
A paper studying a combination cannot isolate the effect of each ingredient. Approval applies to a specific product, formulation, indication, and population, and does not transfer to products with similar names.
Sources, access, and responsible use
Links lead to the original publication or its PubMed record. Legal open-access full text is linked when verified. Other articles may need a journal subscription; we do not reproduce publisher PDFs or full abstracts. Summaries are original educational text, not medical advice.
This library does not provide dosing, sourcing, or treatment recommendations. A small study, an absence of reported harm, or an unstudied claim cannot establish safety. Discuss personal treatment decisions with a qualified clinician.